Literature DB >> 1702354

Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.

P R Wirth1, J Legier, G L Wright.   

Abstract

A panel of seven monoclonal antibodies including anti-vimentin, anti-keratin markers AE1/AE3 and EAB902, human milk fat globule (HMFG-2), B72.3, anti-carcinoembryonic antigen (CEA), and anti-Leu-M1 were used for an immunoperoxidase staining assay to determine their value in the differentiation of pleural mesothelioma from lung adenocarcinoma. Anti-vimentin positively identified 86% of the mesotheliomas and none of the adenocarcinomas. AE1/AE3, EAB902, and B72.3 reacted with a high percentage of both mesothelioma and adenocarcinoma specimens. With HMFG-2, both membrane and cytoplasmic staining was observed in 92% of the adenocarcinomas and in 14% of the mesotheliomas, whereas 26% of the mesotheliomas only exhibited membrane staining. Eighty percent of the adenocarcinomas and 8% of the mesothelioma tissues stained with anti-Leu-M1. Anti-CEA did not react with any of the 50 mesotheliomas tested but did react with 95% of the lung adenocarcinomas tested. From this study, it was concluded that anti-CEA and anti-Leu-M1 were the most effective of the seven tumor markers evaluated; and that 100% of the pleural mesothelioma tissues could be correctly differentiated from lung adenocarcinomas using a panel consisting of anti-vimentin, HMFG-2, anti-CEA and anti-Leu-M1 monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702354     DOI: 10.1002/1097-0142(19910201)67:3<655::aid-cncr2820670322>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.

Authors:  P Athanassiadou; M Gonidi; A Liossi; E Petrakakou; L Nakopoulou; C Zerva; P Athanassiades
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

Authors:  F Roberts; A E McCall; R A Burnett
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

5.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

7.  Mesothelioma-like tumors of the pleura: a review of 72 autopsy cases.

Authors:  C A Hartmann; H Schütze
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

9.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  BMVC test, an improved fluorescence assay for detection of malignant pleural effusions.

Authors:  I-Ting Lin; Yu-Lin Tsai; Chi-Chih Kang; Wei-Chun Huang; Chiung-Lin Wang; Mei-Ying Lin; Pei-Jen Lou; Jin-Yuan Shih; Hao-Chien Wang; Huey-Dong Wu; Tzu-Hsiu Tsai; I-Shiow Jan; Ta-Chau Chang
Journal:  Cancer Med       Date:  2014-01-10       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.